Anumana Receives FDA Clearance for First ECG-AI Algorithm to Detect Early Pulmonary Hypertension
核心洞察
Anumana (搜索) secured FDA 510(k) clearance for the first pulmonary hypertension algorithm designed for standard 12-lead ECGs, marking a breakthrough in early detection capabilities.
The AI algorithm demonstrated 73% sensitivity and 74.4% specificity in detecting pulmonary hypertension among 21,066 patients across five U.S. health systems.
The technology addresses critical diagnostic delays that frequently exceed two years, potentially improving outcomes for patients with this progressive, life-threatening condition affecting up to 1% of the global population.
Anumana (搜索) has achieved a significant regulatory milestone with FDA 510(k) clearance for its pulmonary hypertension (PH) algorithm, marking the first AI-enabled software-as-a-medical-device cleared for detecting early signs of PH using standard 12-lead electrocardiograms. The algorithm, which previously received FDA Breakthrough Device Designation, represents a major advancement in addressing diagnostic challenges for this progressive cardiovascular condition.
Addressing Critical Diagnostic Delays
Pulmonary hypertension affects up to 1% of the global population and presents significant diagnostic challenges due to non-specific early symptoms such as dyspnea. Current diagnostic delays frequently exceed two years, contributing to increased morbidity and mortality rates. The condition is a progressive, life-threatening pulmonary vascular disease affecting the lungs and right side of the heart.
"Pulmonary hypertension is often difficult to recognize until it has progressed significantly, leaving patients and physicians at a disadvantage," said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and a member of the Anumana (搜索) advisory board. "FDA clearance of Anumana's PH algorithm provides clinicians with a practical solution to identify PH earlier and determine appropriate next steps in care, expanding the clinical utility of routine ECGs."
Clinical Performance and Development
The ECG-AI PH algorithm was developed using over 250,000 de-identified patient records from Mayo Clinic. In an independent, multi-center study involving 21,066 patients across five U.S. health systems, the algorithm demonstrated 73% sensitivity and 74.4% specificity in detecting PH among adult patients presenting with dyspnea.
Additional real-world analysis revealed promising results for specific PH subtypes. In patients with an ECG available between symptom onset and PH diagnosis, the algorithm identified more than 85% of patients with pulmonary arterial hypertension (PAH) and 78% with chronic thromboembolic pulmonary hypertension (CTEPH), suggesting potential for earlier detection of these treatable PH subgroups.
Technology Integration and Accessibility
The algorithm enhances standard 12-lead ECGs by detecting subtle abnormalities that may not be visible to clinicians, helping identify when follow-up testing such as echocardiography is warranted. The technology integrates with electronic health record systems, including ECG management platforms, and operates entirely within the health system environment without transferring patient data.
"The FDA clearance of our Pulmonary Hypertension algorithm is the result of rigorous clinical development and regulatory work, and it marks a meaningful step toward expanding access to AI-enabled insights at the point of care," said Simos Kedikoglou, President & COO of Anumana (搜索). "As the first PH algorithm cleared for use with standard 12-lead ECGs, it is broadly accessible across care settings, integrates directly into existing clinical workflows, and supports clinical decision-making in real time."
Company Background and Future Outlook
Anumana (搜索), co-founded by nference (搜索) and Mayo Clinic, specializes in AI-driven cardiovascular health technology solutions. The company develops software-as-a-medical-device solutions that apply multimodal AI to support early detection, clinical decision-making, and intraoperative guidance across the continuum of care.
This clearance expands Anumana (搜索)'s portfolio of FDA-cleared ECG-based algorithms, which are currently available in the U.S. and eligible for reimbursement. The milestone reflects the company's broader vision to expand the role of ECGs in identifying cardiovascular risk earlier and at scale, delivering clinically validated solutions across diverse care settings worldwide.